Speciality chemicals company Clariant has expanded its Clear Lake site to include excipient GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients.
The company said the move significantly improves its availability and reliability for North American customers, with extended reach to Latin America.
Clariant's multi-phase expansion has focused on key industry priorities, including supply chain security and responsiveness, which the company says highlights its commitment to the US pharmaceutical market.
The Clear Lake facility will be Clariant's first US site for producing pharmaceutical-grade PEG excipients—a significant step in its healthcare growth strategy.
By establishing regional production, the firm aims to enhance the resilience and responsiveness of the supply chain for pharmaceutical manufacturers in the area.
The Clear Lake facility will also provide Clariant with important operational benefits for pharmaceutical customers.
Regional manufacturing will reduce lead times, enabling quicker responses to market demand, lower inventory costs and enhanced competitive pricing.
Improved supply continuity will give pharmaceutical manufacturers the reliability they need for complex production schedules and regulatory compliance.
"This expansion strengthens our ability to provide reliable local supply and positions us as a true partner to the North American pharmaceutical industry," said Vaios Barlas, Head of Health Care at Clariant.
In addition to greater manufacturing capacity, we're fundamentally transforming how we serve our customers by bringing production closer to their operations and accelerating more responsive, collaborative relationships.
Clariant added that the upgrades and operations at the Clear Lake facility were designed to meet the highest quality, safety and regulatory standards of the pharmaceutical industry.
Ensuring excipient GMP compliance means that all manufacturing processes adhere to international standards for pharmaceutical excipients. This provides customers with the necessary documentation, traceability and quality assurance required for regulated pharmaceutical production.